Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients

Published 01/11/2022, 07:23 AM
Updated 01/11/2022, 10:51 PM
© Reuters. FILE PHOTO: A sign marks a Biogen facility in Boston, U.S., March 9, 2020. REUTERS/Brian Snyder
LLY
-
BIIB
-
RHHVF
-
ESAIY
-

By Deena Beasley and Leroy Leo

(Reuters) -The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc (NASDAQ:BIIB)'s Aduhelm but will require patients to be enrolled in a clinical trial, limiting access to the treatment more than many expected.

Biogen shares were down 7.3% at $224 in extended trading on Tuesday. Shares of Biogen's Japanese partner Eisai Co (OTC:ESALY) Ltd slid 2.6% in Tokyo.

The decision from the U.S. Centers for Medicare and Medicaid Services (CMS), the health agency that runs Medicare, could change as it seeks comment from companies and patients. A final decision is due on April 11.

The final CMS coverage terms are expected to apply to all drugs in the class, including experimental medications in development by Eli Lilly & Co (NYSE:LLY), Roche Holding AG (OTC:RHHVF) and Eisai.

Patient advocacy group UsAgainstAlzheimer’s chairman George Vradenburg said he was angry Medicare placed conditions on the use of the drugs that were more limiting than the regulator, the Food and Drug Administration, put on Aduhelm, and that the Medicare decision applied to any amyloid drug.

The government's health service was "at war with itself," he said.

"The FDA has approved this drug and now Medicare has disapproved the drug," Vradenburg said.

The FDA approved the drug in June last year despite its 11-member committee of outside experts voting nearly unanimously in November 2020 that the drug should not be approved, citing inconclusive evidence the drug was effective.

Many experts have questioned the FDA's rationale for Aduhelm's approval without more definitive proof of benefit, and doctors have held back on prescribing it.

"The wholesale rejection of this product by payers and health systems around the country is notable but not shocking, given how little evidence the manufacturer produced at the time of its FDA approval," said Dr. Caleb Alexander, a professor with the Johns Hopkins Center for Drug Safety and Effectiveness, in Baltimore. Alexander was a member of the FDA advisory panel that voted not to approve the drug.

Demand for an Alzheimer's treatment, he said, "should fuel our investments in drug development, not a lowering of standards that Americans rely upon to know whether their drugs are safe and effective."

UNUSUAL RESTRICTIONS

The unusual move to require clinical trials for recipients of the already approved drug comes after a six-month process in which CMS had been working on a national coverage policy for the drug.

The decision to require the trial "will exclude almost all patients who may benefit," Biogen said in a statement.

The requirements "can take months to years to initiate," it said, and promised to urge the agency to align its coverage policy with the populations that have been studied in previous clinical trials.

"We believe Alzheimer's patients should have access consistent with other therapies with FDA accelerated approval," Biogen said.

Sales so far have been weak and Biogen last month cut the medication's list price by about half to $28,200 per year.

Cowen analyst Eric Assaraf said in a research note the decision to restrict coverage to clinical trial participants was more restrictive than he had expected, noting the agency could have simply required Biogen to maintain a registry of patients that documented responses to the drug. He said CMS may change its stance in the final decision.

Aduhelm's high price also has raised concerns over the toll it might take on the Medicare program, the U.S. government health plan for people age 65 and over. Because Alzheimer's is an age-related disease, around 85% of people who might use the medicine are in the government plan.

With the proposed decision, the cost will shift to patients, Vradenburg said.

© Reuters. FILE PHOTO: A sign marks a Biogen facility in Boston, U.S., March 9, 2020. REUTERS/Brian Snyder

"Unless you are a very wealthy person, you are not going to get access to the drug," he added.

Aduhelm, given as a monthly infusion, is a monoclonal antibody designed to remove a type of brain plaque associated with Alzheimer's Disease. Patients need to be monitored for potential side effects including brain swelling.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.